Shares of Sarepta Therapeutics (SRPT +2.7%) rebound from Wednesday's sell-off.
Perhaps helping to allay fears is TheStreet's Adam Feuerstein who penned a "rousing rebuttal" to the two SRPT short articles that appeared on SA Wednesday.
"Neither article said anything new about SRPT or eteplirsen that hasn't been already debated endlessly," Feuerstein says, adding that "the eteplirsen data are what they are [and] investors find the data convincing or not."
Feuerstein also notes that there will likely never be an "apples-to-apples comparison of dystrophin production between eteplirsen and drisapersen" but the data certainly seems to suggest that eteplirsen "produces more functional dystrophin."
For reference, see: SRPT falls as article questions eteplirsen study.